Dronabinol - Hoverink Biotechnologies
Alternative Names: LADAVRULatest Information Update: 28 Jun 2022
At a glance
- Originator Hoverink Biotechnologies
- Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer pain; Chemotherapy-induced nausea and vomiting
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer-pain in USA (IV, Injection)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer-pain in USA (PO)
- 28 May 2022 No recent reports of development identified for research development in Chemotherapy-induced-nausea-and-vomiting in USA (IV, Injection)